NCT00400218已完成3 期
Evaluate the Safety and Tolerability of Hyzaar(R) (Losartan 50 Mg/ Hydrochlorothiazide 12.5 Mg) In the Treatment of Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 62
- 主要终点
- Blood pressure over 12 weeks
研究概览
简要总结
Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is either receiving high blood pressure monotherapy or no treatment
- •Patient will have reached the legal age by the time enter the study
- •Patients diagnosed with mild to moderate essential high blood pressure or high blood pressure with other conditions such as diabetes or cardiovascular diseases and are taking high blood pressure medication (exclude diuretic), but did not meet treatment goal
排除标准
- •Patient with high levels of uric acid in the blood who has received medications for uric acid in the urine within 3 months prior to enrollment
- •Patients who are hypersensitive to any component of the study medication
- •Patients who are hypersensitive to other sulfonamide-derived drugs
- •Patients with anuria (hyzaar(R) is not recommended for patients with hepatic impairment or severe renal impairment, creatinine clearance </= 30 ml/min)
- •Unstable diabetes (hba1c > 8%), or a change in diabetes medication during study treatment. patients with stable diabetes may enter the study.
结局指标
主要结局
Blood pressure over 12 weeks
Safety and Tolerability.
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)HypertensionNCT00398541Organon and Co41
已完成
3 期
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate HypertensionHypertensionNCT00095550Bristol-Myers Squibb496
进行中（未招募）
1 期
HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy - HYPAZ: Hypertension induced by pazopanibHypertension induced by pazopanib treatment of various cancer typesMedDRA version: 16.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021613-23-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge27
已完成
2 期
Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)Essential HypertensionNCT00937651Boryung Pharmaceutical Co., Ltd81
已完成
3 期
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe HypertensionHypertensionNCT00095394Bristol-Myers Squibb645